<DOC>
	<DOCNO>NCT01207388</DOCNO>
	<brief_summary>The purpose study confirm whether bispecific T cell engager blinatumomab ( MT103 ) effective , safe tolerable treatment ALL patient minimal residual disease .</brief_summary>
	<brief_title>Confirmatory Phase II Study Blinatumomab ( MT103 ) Patients With Minimal Residual Disease B-precursor Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>The detection minimal residual disease ( MRD ) induction therapy and/or consolidation therapy independent prognostic factor poor outcome adult ALL . No standard treatment available patient MRD-positive B-precursor ALL . Blinatumomab ( MT103 ) bispecific single-chain antibody construct design link B cell T cell result T-cell activation cytotoxic T-cell response CD19 express cell . The purpose study confirm whether bispecific T-cell engager blinatumomab ( MT103 ) effective , safe tolerable treatment ALL patient minimal residual disease . Participants receive four 4-week cycle intravenous blinatumomab treatment follow infusion-free period 14 day . A safety follow-up perform 30 day end last infusion efficacy follow-ups occur 24 month treatment start . Participants follow 5 year start treatment survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Patients Bprecursor ALL complete hematological remission least 3 intense chemotherapy block Presence minimal residual disease level â‰¥ 10^3 Availability bone marrow specimen primary diagnosis clonespecific MRD assessment Negative human immunodeficiency virus ( HIV ) test , negative hepatitis B ( HbsAg ) test hepatitis C virus ( antiHCV ) test Negative pregnancy test woman childbearing potential Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Presence circulate blast current extramedullary involvement ALL History relevant central nervous system ( CNS ) pathology current CNS pathology Prior allogeneic hematopoietic stem cell transplant ( HSCT ) Eligibility treatment tyrosinekinase inhibitor ( TKI ) Systemic cancer chemotherapy within 2 week prior study treatment Therapy monoclonal antibody ( rituximab , alemtuzumab ) within 4 week prior study treatment Previous treatment blinatumomab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Blinatumomab</keyword>
	<keyword>MRD</keyword>
	<keyword>B-ALL</keyword>
	<keyword>Minimal residual disease</keyword>
	<keyword>adult ALL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Lymphatic disease</keyword>
	<keyword>Lymphoproliferative disorder</keyword>
	<keyword>bispecific antibody</keyword>
	<keyword>anti-CD19</keyword>
	<keyword>Immunotherapeutic treatment</keyword>
</DOC>